Global Legionellosis Market, By Type (Pneumonic, Non-Pneumonic, Others), Diagnosis (Blood and Urine Tests, Chest X-ray, Sputum and Lung Tissue, Others), Treatment (Medication, Sooner Therapy, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the legionellosis market is anticipated to grow rapidly during the forecast period. According to the Centers for Disease Control and Prevention (CDC), there were 6,238 cases of legionnaires disease in the United States in 2017. While this is a modest incidence rate, it represents a 13.6 percent increase in the number of cases when compared to 2016 predictions. Although legionellosis disease is not contagious, it can be spread by contaminated water droplets and mist. Legionellosis disease is an infrequent and sporadic respiratory infection in the EU countries, similar to the United States, with low notification rates.
Data Bridge Market Research analyses that the legionellosis market was valued at USD 1.2293 billion in 2021 and is expected to reach USD 2.36 billion by 2029, registering a CAGR of 8.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Legionellosis is a severe form of pneumonia caused by the Legionella pneumophila bacterium. Legionella bacteria can be found in ponds, rivers, hot springs, creeks, and other bodies of water. Inhalation of contaminated aerosols from air conditioning cooling towers, humidifiers, hot and cold water systems, artificial fountains, and whirlpool spas can spread Legionella species. However, it cannot be passed from one individual to another. Fever, chills, headache, malaise, and muscle soreness are all symptoms of legionellosis, but in severe cases, mortality can result from respiratory failure, shock, and multi-organ failure.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Pneumonic, Non-Pneumonic, Others), Diagnosis (Blood and Urine Tests, Chest X-ray, Sputum and Lung Tissue, Others), Treatment (Medication, Sooner Therapy, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Fresenius Kabi AG (Germany), Almirall, S.A (Spain), Baxter (US), Hikma Pharmaceuticals PLC (UK)
|
|
Market Opportunities
|
|
Legionellosis Market Dynamics
Drivers
- Increasing prevalence of chronic illness
The rising prevalence of chronic illness is estimated to enhance the legionellosis market's growth. A growing proportion of smokers along with diabetes, HIV, cancer, kidney disease, or other chronic conditions are at risk of infection and hospitalization and this will further propel the growth rate of market.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of legionellosis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get legionellosis infections, further estimated to enhance the market’s growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the legionellosis market. Additionally, rising incidences of pneumonia and surging demand for rapid and advanced diagnostic techniques will result in the expansion of legionellosis market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the legionellosis market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the legionellosis market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the legionellosis market. Additionally, insufficient disposable income in developing as well as underdeveloped countries and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This legionellosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the legionellosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Legionellosis can affect anybody, although it is more prevalent and severe among the elderly (typically over 50), smokers (current or past), persons with underlying lung illness (such as emphysema), and people with compromised immune systems. Healthy people who come into touch with the bacteria may experience no symptoms or only a mild sickness.
Legionellosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Legionellosis Market
Over the projected period, the legionellosis market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The legionellosis market has also been hampered by the supply chain slowness.
Global Legionellosis Market Scope
The legionellosis market is segmented on the basis of type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Pneumonic
- Non-Pneumonic
- Others
Treatment
- Medication
Antibiotics
- Sooner Therapy
- Others
Diagnosis
- Blood and Urine Tests
- Chest X-ray
- Sputum and Lung Tissue
- Others
Dosage form
- Tablets
- Capsules
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Legionellosis Market Regional Analysis/Insights
The legionellosis market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Legionellosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the legionellosis market because of the growing prevalence of legionellosis in this region. Additionally, rising healthcare expenditure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and increased government and WHO awareness programs in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Legionellosis Market Share Analysis
The Legionellosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to legionellosis market.
Some of the major players operating in the legionellosis market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Abbott (US)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
- Fresenius Kabi AG (Germany)
- Almirall, S.A (Spain)
- Baxter (US)
SKU-